search icon
  • What's New in Practice Management & Payment

    CMS: Fact Sheet for the QPP Year 2 Proposed Rule

    AMA Releases New MIPS Resources

    CMS Releases Lookup Tool to Help Clinicians Determine their MIPS Participation Status

    CMS: New Quality Payment Program Resources Available

    MIPS 2017: Important Dates & Information

  • Upcoming Meetings

    IDWeek 2017 logo
    There are no upcoming events at this time.

The HIV Medicine Association is an organization of medical professionals who practice HIV medicine. We represent the interests of our patients by promoting quality in HIV care and by advocating for policies that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice.

  • Policy News

    IDSA Leads Call for Antimicrobial Resistance Funding

    The Infectious Diseases Society of America has sent a letter signed by more than 60 organizations urging congressional appropriations leaders to reject President Trump's  proposed cuts to federal funding for efforts to confront antimicrobial resistance and to maintain the bipartisan commitment to this issue.  The letter details why a multifaceted domestic and global response is required to stem the threat antimicrobial resistance poses to patient safety and public health.

  • Breaking News and Alerts

    6/26/2017 3:24:42 PM

    FDA approves new fluoroquinolone antibiotic to treat bacterial skin infections

    The U.S. Food and Drug Administration today approved Baxdela (delafloxacin), a new antibacterial drug to treat acute bacterial skin and skin structure infections. Baxdela is available for intravenous and oral use.

    5/22/2017 2:17:49 PM

    Ongoing Transmission of Candida auris in Health Care Facilities

    CDC has just released an MMWR update on Candida auris (C. auris) cases identified in U.S. health care facilities through May 2017.

    5/18/2017 1:29:25 PM

    Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers

    The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about the use of Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare Plus) with venous blood samples because they might result in falsely low test results. FDA is now advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick. The purpose of this Health Advisory is to notify state and local health departments, healthcare providers, and laboratories about CDC’s re-testing guidance in light of the safety alert.

    6/12/2017 1:00:29 PM

    Prolonged IgM Antibody Response in People Infected with Zika Virus: Implications for Interpreting Serologic Testing Results for Pregnant Women

    In July 2016, CDC issued Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure – United States, July 2016 ( that includes Zika virus immunoglobulin M (IgM) testing of pregnant women.

    5/4/2017 10:03:31 AM

    U.S.-licensed yellow fever vaccine supply to be depleted by mid-2017

    The Centers for Disease Control and Prevention outlines a plan to ensure a continuous yellow fever vaccine supply in the United States following the anticipated depletion of the U.S.-licensed YF-VAX® yellow fever vaccine in mid-2017, according to a Morbidity and Mortality Weekly Report published April 28, 2017.

    4/10/2017 12:24:52 PM

    FDA approves two hepatitis C drugs for pediatric patients

    The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.

    4/4/2017 3:21:04 PM

    CDC: About 1 in 10 U.S. pregnant women with confirmed Zika infection had a fetus or baby with birth defects in 2016

    Of the 250 pregnant women who had confirmed Zika infection in 2016, 24 – or about 1 in 10 of them – had a fetus or baby with Zika-related birth defects, according to a new Vital Signs report from the Centers for Disease Control and Prevention (CDC). This report is the first to provide the analysis of a subgroup of pregnant women in the U.S. with clear, confirmed test results of Zika virus infection.

    3/27/2017 12:24:20 PM

    CDC Updates Specimen Collection, Shipping, and Testing Guidance for Suspected Acute Flaccid Myelitis (AFM) Cases

    Despite extensive pathogen-specific testing of many specimens since 2014, CDC and others have not identified an etiology for the AFM cases. Therefore, CDC will no longer perform clinical diagnostics for enteroviruses or metagenomic sequencing on specimens collected from suspect cases of AFM.

  • News from IDSA and the Journals

    IDSA, AASLD Express Concerns About Cochrane Review of DAAs for Hep C


    We are writing to express our serious concerns regarding the recent Cochrane Group Review concluding that there is a lack of valid evidence supporting the benefit of direct acting antiviral (DAA) therapy for chronic infection with hepatitis C virus (HCV), and its supposition: “the possibility of potentially harming people with chronic hepatitis ought to be considered before treating people with hepatitis C with DAAs.”

| IDSA | Contact Us

© Copyright HIVMA 2017 HIV Medicine Association

Full Site Mobile Site